Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Chronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Published

on

<!– Name:DistributionId Value:8831876 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:bf93d34a-c29f-41bf-9b96-ebcbd79d48bd –>

New York, USA, May 08, 2023 (GLOBE NEWSWIRE) — Chronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Chronic kidney disease (CKD) is a debilitating condition that affects people all over the world, and it is one of a small number of non-communicable diseases that have shown an increase in associated deaths over the past two decades. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and people experiencing diabetes mellitus and hypertension. This increasing prevalence is expected to create a favorable environment for novel products to succeed. Companies all across the world have moved their focus to CKD treatment. The rise in incidence will boost the market for CKD treatment.

DelveInsight’s Chronic Kidney Disease Pipeline Insight 2023 report provides comprehensive global coverage of pipeline chronic kidney disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the chronic kidney disease pipeline domain.

Key Takeaways from the Chronic Kidney Disease Pipeline Report

  • DelveInsight’s chronic kidney disease pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for chronic kidney disease treatment. 
  • Key chronic kidney disease companies such as Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others are evaluating new chronic kidney disease drugs to improve the treatment landscape.
  • Promising chronic kidney disease pipeline therapies such as Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others are under different phases of chronic kidney disease clinical trials.
  • In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species: mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in the Phase 2 clinical program for ADPKD.
  • In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. 
  • In January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company  announced. 
  • In November 2022, the Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance® (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P<0.0001).
  • In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose-dependent manner in the medium and high dose groups (21.7% reduction (p <0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF-β inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)).
  • In October 2022, French Biopharma Company Poxel SA announced the U.S. Food and Drug Administration (FDA) had granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2-ready ADPKD asset, subject to additional financing.

Request a sample and discover the recent advances in chronic kidney disease treatment drugs @ Chronic Kidney Disease Pipeline Report

The chronic kidney disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage chronic kidney disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the chronic kidney disease clinical trial landscape.

Chronic Kidney Disease Overview

Chronic kidney disease occurs when the kidneys are damaged and unable to filter blood. As a result, additional blood fluid and waste linger in the body, potentially contributing to various health problems such as heart disease and stroke. The severity of chronic kidney disease varies. It usually worsens over time, but treatment has been demonstrated to reduce the progression. If chronic kidney disease is not treated, it can lead to renal failure and early cardiovascular disease. Chronic kidney disease is more common in the elderly. In the United States, it is the leading cause of death. It is believed that 37 million US adults have chronic kidney disease, with the majority going undetected. Early-stage kidney disease typically has no symptoms, and many people are unaware they have chronic kidney disease until it is well advanced.

Chronic kidney disease patients may not feel poorly or notice any signs. If kidney disease proceeds slowly, CKD signs and symptoms develop over time. Kidney failure can result in an accumulation of fluid or waste, as well as electrolyte imbalances. Chronic kidney disease symptoms include hypertension, anemia, edoema, weariness, decreased urine output, blood in urine, dark urine, lack of appetite, and persistent itching skin. 

Find out more about chronic kidney disease treatment drugs @ Drugs for Chronic Kidney Disease Treatment

A snapshot of the Chronic Kidney Disease Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
Empagliflozin Boehringer Ingelheim/Eli Lilly and Company Preregistration Sodium-glucose transporter 2 inhibitors Oral
Bardoxolone methyl  Reata Pharmaceuticals Phase III Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors Oral
KBP-5074 KBP Biosciences Phase III Mineralocorticoid receptor antagonists Oral
Ziltivekimab Novo Nordisk Phase III Interleukin 6 inhibitors Subcutaneous
US-APR2020 Kibow Pharma Phase II/III Bacteria replacements; Microbiome modulators Oral
DM199 DiaMedica Therapeutics Phase II Tissue kallikrein replacements Subcutaneous
Sucunamostat  SCOHIA PHARMA/Takeda Phase II Enteropeptidase inhibitors Oral
AL-01211 AceLink Therapeutics Phase I Glucosylceramide synthase inhibitors Oral

Learn more about the emerging chronic kidney disease pipeline therapies @ Chronic Kidney Disease Clinical Trials

Chronic Kidney Disease Therapeutics Assessment

The chronic kidney disease pipeline report proffers an integral view of the chronic kidney disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Chronic Kidney Disease Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Mineralocorticoid receptor antagonists, Interleukin 6 inhibitors, Bacteria replacements, Microbiome modulators, Tissue kallikrein replacements, Glucosylceramide synthase inhibitors, Sodium-glucose transporter 2 inhibitors, Cyclo-oxygenase 2 inhibitors, I-kappa B kinase inhibitors, NF E2 related factor 2 stimulants, NF-kappa B inhibitors, Nitric oxide synthase type II inhibitors, STAT3 transcription factor inhibitors, Enteropeptidase inhibitors
  • Key Chronic Kidney Disease Companies: Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others
  • Key Chronic Kidney Disease Pipeline Therapies: Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others

Dive deep into rich insights for new drugs for chronic kidney disease treatment, visit @ Chronic Kidney Disease Drugs

Table of Contents

1. Chronic Kidney Disease Pipeline Report Introduction
2. Chronic Kidney Disease Pipeline Report Executive Summary
3. Chronic Kidney Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Kidney Disease Clinical Trial Therapeutics
6. Chronic Kidney Disease Pipeline: Late Stage Products (Pre-registration)
7. Chronic Kidney Disease Pipeline: Late Stage Products (Phase III)
8. Chronic Kidney Disease Pipeline: Mid Stage Products (Phase II)
9. Chronic Kidney Disease Pipeline: Early Stage Products (Phase I)
10. Chronic Kidney Disease Pipeline Therapeutics Assessment
11. Inactive Products in the Chronic Kidney Disease Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Chronic Kidney Disease Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the chronic kidney disease pipeline therapeutics, reach out @ Chronic Kidney Disease Treatment Drugs

Related Reports

Chronic Kidney Disease Epidemiology Forecast

Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Kidney Disease Market

Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, among others.

Moderate and Severe Chronic Kidney Disease Market

Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including  Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.

Moderate and Severe Chronic Kidney Disease Pipeline

Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including  Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.

Anemia In Chronic Kidney Disease Market

Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including  Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.

Anemia In Chronic Kidney Disease Pipeline

Anemia In Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anemia in chronic kidney disease companies, including  Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Chronic Kidney Disease Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Appdome Sweeps Cybersecurity Excellence Awards

Published

on

appdome-sweeps-cybersecurity-excellence-awards

Unified Mobile Defense Platform Recognized for Innovation and Leadership Across Nine Cybersecurity Categories
REDWOOD CITY, Calif., May 21, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile defense, today announced it has received a total of nine (9) Cybersecurity Excellence Awards. The Appdome Unified Mobile App Defense Platform was awarded best in class across nine categories in recognition of the comprehensive breadth, depth and value of the Appdome platform to brands and enterprises alike.

“We congratulate Appdome on being recognized as an award winner in 9 categories of the 2024 Cybersecurity Excellence Awards,” said Holger Schulze, CEO of Cybersecurity Insiders and founder of the 600,000-member Information Security Community on LinkedIn, which organizes the 9th annual Cybersecurity Excellence Awards. “With over 600 entries across more than 300 categories, the awards are highly competitive. Appdome’s achievement reflects outstanding commitment to the core principles of excellence, innovation, and leadership in cybersecurity.”
Within a single pane of glass, Appdome delivers the most complete set of no-code, no-SDK, fully automated mobile defenses to mobile brands and enterprises, empowering mobile developers, cybersecurity, fraud and IT teams to deliver on any mobile cyber objective quickly and easily.
The nine (9) categories in which Appdome received a Cybersecurity Excellence Award are:
Mobile Security Platform: Appdome is the only enterprise-grade mobile security platform built for full mobile defense lifecycle management, visibility and control to brands and enterprises alike, including key features for build, test, release, monitor, response, and compliance automation. Mobile Security Automation: Appdome is the only mobile defense solution that uses machine learning to code and build over 300+ mobile app security, anti-fraud, anti-cheat, anti-malware, anti-bot, geo-compliance and other defenses in Android & iOS apps in the DevOps pipeline.Mobile Social Engineering Defense:  The Appdome Social Engineering Prevention solution is the first of its kind to protect mobile users from voice phishing (Vishing) scams and other imposter scams, T.O.A.D. attacks, Remote Access Trojans (RATs), Gold Pickaxe, FaceID bypass and more without an SDK or external servers.Mobile Bot Defense: The Appdome MOBILEBot™ Defense solution is the first mobile anti-bot solution to come out of the box compatible with any industry standard web application firewall (WAF) on the market and provide multi-layered bot, credential stuffing and Account Take Over (ATO) defense without an SDK, external server, performance limits, or restrictions.Mobile Geo Compliance:  Only the Appdome Mobile Geo-Compliance solution guarantees accurate and authentic geo location of mobile devices, applications and users without code or coding in the mobile app, without implementing an SDK and without deploying additional servers.Mobile XDR: The Appdome ThreatScope™ Mobile XDR solution is the only mobile attack and threat monitoring service that comes pre-packaged into the mobile defense lifecycle, requires no device agent, device profile, separate code, coding, SDK or server, and provides real-time detection and automated response across internal (employee facing) and external (consumer facing) Android & iOS apps.DevOps Mobile Security Tool: The Appdome platform’s fully integrated Security Release Management™ capabilities and Appdome Certified Secure™ mobile DevSecOps certification offer the only true enterprise-grade compliance assurance, audit and control for mobile defense at brands and enterprises, allowing quick verification that all security, anti-fraud and compliance objectives have been met.   Mobile Application Security:  With 300+ separate defenses for mobile apps, Appdome has the most comprehensive set of mobile application security features available in one product, fully compatible with all mobile Android & iOS apps.”Nine Cybersecurity Excellence Awards for Mobile Defense tells a very compelling story for the incredibly complex Dev, Sec, and Ops challenges organizations face detecting and defeating mobile-based risks and attacks,” said Chris Roeckl, Chief Product Officer at Appdome. “Point products make these challenges worse by adding complexity and overloading already taxed cyber and engineering teams. Appdome is the only platform simplifying work, bringing all these unique challenges under a single pane of glass, delivering 300+ protections and simultaneously resolving the security, fraud, resilience and compliance challenges brands and enterprises face.”
Learn more about the award-winning Appdome Platform at www.appdome.com or request a personalized demo at https://www.appdome.com/request-a-demo/appdome-home/
The full list of awards are available from the Cybersecurity Excellence Awards website  https://cybersecurity-excellence-awards.com/
About AppdomeThe Appdome mission is to protect every mobile app and mobile user in the world. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control, and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
Logo – https://mma.prnewswire.com/media/772169/AppDome_Logo_9_27_23.jpg

View original content:https://www.prnewswire.co.uk/news-releases/appdome-sweeps-cybersecurity-excellence-awards-302151786.html

Continue Reading

Artificial Intelligence

Courageous Whistleblowers Reclaim Derogatory Terms As Data Shows 80% of Financial Professionals Stay Silent on Suspected Internal Fraud, Fearing Retaliation

Published

on

courageous-whistleblowers-reclaim-derogatory-terms-as-data-shows-80%-of-financial-professionals-stay-silent-on-suspected-internal-fraud,-fearing-retaliation

Enron whistleblower, Sherron Watkins, alongside stars of Apple TV’s The Big Conn, Sarah Carver and Jennifer Griffith, reclaim derogatory labels for whistleblowers          Concerning new data shows more than half of financial professionals in the UK and US have spotted or suspected internal fraud in their workplaces, yet four out of five stay silent fearing retaliation          32% of professionals in finance have seen whistleblowers victimized behind their back or to their faceJACKSONVILLE, Fla., May 21, 2024 /PRNewswire/ — New data from fraud detection software company Medius shows more than half of financial professionals in the UK and US (56%) have spotted or suspected internal fraud in their workplaces yet four in five (81%) stayed silent. When asked why, 45% of professionals cited the fear of recrimination.

Whistleblowers Sherron Watkins, Sarah Carver and Jennifer Griffith have joined forces to reclaim the derogatory names they were called after reporting serious internal financial fraud.
To help empower others to come forward, the whistleblowers are reclaiming the terms “snitch”, “rat” and “traitor”.
Sherron Watkins is the former Vice President of Enron Corporation who alerted the CEO to accounting irregularities, warning the organization “‘might implode in a wave of accounting scandals.” Watkins received national acclaim for her courageous actions and TIME magazine named her along with two others as their Persons of the Year in 2002, calling them simply ‘The Whistleblowers.’
Sarah Carver and Jennifer Griffith are the stars of Apple TV’s The Big Conn after they exposed a fraud scheme of more than $550 million while employed at the Social Security Administration. In efforts to silence their disclosures, they experienced multiple acts of severe retaliation and were denied protection. Ultimately, both Carver and Griffith were forced from employment.
Concerns of repercussions are vindicated – the survey reveals the extent to which financial professionals in the UK and US have witnessed negative consequences for whistleblowers firsthand:           
59% have seen whistleblowers subsequently left out of important decisions           33% have seen whistleblowers moved to a different team           32% have heard whistleblowers called derogatory names behind their backs or directly to their faceWhen asked what would encourage them to flag suspicious activity, 93% of workers surveyed would feel more comfortable doing so if they had more evidence, yet nearly half (48%) said the legal system simply does not adequately protect whistleblowers.
Jim Lucier, CEO at Medius, a leading global provider of cloud-based accounts payable automation and spend management solutions, said:
“White collar crime is on the rise and no organization is safe. Employees are the last line of defense against fraud but confidence to report suspicious activity is declining. AI anomaly-detection technology can provide employees with the evidence and assurances they need to be more forthcoming. Building a culture where employees feel comfortable to report their suspicions could save organizations millions in the long-run.”
Medius works with over 4,000 customers across 102 countries and processes $200 billion in annual spend. It uses the power of AI and automation to detect fraud the moment invoices are submitted safeguarding against bad actors and potential threats, internal and external.
Sherron Watkins, whistleblower who was called a “snitch”, said: “When someone is troubled by corporate wrongdoing and they attempt to sound the alarm, the pathway is uncharted, things happen organically. Normal rational people speak about their concerns with their closest friends and work colleagues, who often suggest staying safe saying “keep your head down, if you must report, go soft, nothing black and white.” Yet black and white evidence is what is needed to get the attention of those in power, either internally or with media or outside watchdog groups to prevent or stop fraudulent activity.”  
Jennifer Griffith, whistleblower who was called a “traitor”, said: “Choosing to blow the whistle involves more than just the desire to right a wrong.  It’s about protecting their employers from fraud. However, it’s more often than not seen as causing trouble for the employer, or as a self-serving action to get a financial reward. No one who chooses to blow the whistle expects to have their reputation attacked, their credibility impugned or to lose their job. The cost of ignoring a whistleblowers complaints are far greater than acknowledging that a problem exists and taking steps to fix it.  It’s been 19 years since I blew the whistle and the problems that existed then with the Social Security Administration still exist today. We must do more to protect whistleblowers.”
Sarah Carver, whistleblower who was called a “rat”, said: “The government’s attempt to conceal the fraud resulted in exacerbated damage, whereas a more prudent approach would have entailed immediate acknowledgement and rectification upon initial disclosure. The retaliatory measures aimed at silencing me made me stronger and fight harder to find someone to listen and stop the fraud.”
Georgina Hallford-Hall, CEO of Whistleblowers UK, said: “Too many organisations talk the talk but fail to engage with whistleblowers often at great cost to both. Technology used properly can remove the fear that both organisations and whistleblowers have about dealing with whistleblowing because it removes the person and focuses on the concerns or malfeasance. WhistleblowersUK are calling on the UK government to introduce an Independent Office of the Whistleblower to protect everyone from discrimination setting standards that end stigmatisation and discrimination making it safe to speak up.”
The billboard advertising campaign runs on Wall Street from Saturday, 18th May to Friday, 24th May 2024.
For more information about how Medius can prevent fraud, visit: https://www.medius.com/whistleblowing/
Notes to Editor
Methodology
The research was conducted by Censuswide with 1500 financial professionals in the UK and US (aged 18+) between 04/22/24 – 05/07/24. Censuswide abide by and employ members of the Market Research Society which is based on the ESOMAR principles and are members of The British Polling Council.
For more information, please contact: 
Fight or Flight for [email protected] / +44 330 133 0985
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medius/r/snitch—traitor—rat–courageous-whistleblowers-reclaim-derogatory-terms-as-data-shows-80–of-fina,c3985054

View original content:https://www.prnewswire.co.uk/news-releases/courageous-whistleblowers-reclaim-derogatory-terms-as-data-shows-80-of-financial-professionals-stay-silent-on-suspected-internal-fraud-fearing-retaliation-302151622.html

Continue Reading

Artificial Intelligence

ThroughPut.AI and Inteligistics Announce Strategic Partnership to Transform Agriculture and Fresh Produce Supply Chains

Published

on

throughput.ai-and-inteligistics-announce-strategic-partnership-to-transform-agriculture-and-fresh-produce-supply-chains

The Partnership focuses on driving maximum optimization of both the supply chain and interwoven cold chain to improve sales, profit margins, output, safety, and traceability.
PALO ALTO, Calif., May 21, 2024 /PRNewswire/ — ThroughPut Inc., the industrial AI supply chain Decision Intelligence pioneer, and Inteligistics, the leading digital visibility solutions provider for perishable supply chains, today announced a strategic technology alliance to accelerate profitability for the sales of perishable goods. This area is typically plagued by volatile prices and volumes, poor predictions, limited supply chain visibility, and excessive product spoilage. This leads to high rejection and discount rates, and avoidable lost margins. ThroughPut.AI, in collaboration with Inteligistics, will enable growers, suppliers, carriers, distributors, and retailers to significantly improve the efficiency of their supply and cold chain operations, thus ensuring that all fresh products – ranging from berries and vegetables to fish and meat – is sold profitably on-time and in-full for faster, fresher and safer delivery with full supply chain visibility.

Mutual customers introduced ThroughPut.AI and Inteligistics as complementary partners due to ThroughPut.AI’s patented, Gartner-ranked comprehensive Supply Chain Analytics & Decision Intelligence software, with Inteligistics’ industry-leading expertise in supply chain performance, productivity, and sustainability, where both have yielded high-value outcomes for customers, their consumers, and owner-investors across the globe. The two companies also share a common goal of minimizing waste, shrink, unfilled orders, and lost sales.
“We’re delighted to partner with Inteligistics as we look to expand our capabilities for our clients in the critical Food and Agricultural industry. Food and AG supply chains suffer from siloed legacy point solutions that don’t address today’s supply chain networks’ complexity and volatility. To overcome these modern Food and AG supply chain challenges, already existing but disparate data must be tapped into, stitched together, analyzed, visualized, and optimized with Industrial-grade AI for actionable recommendations and better results,” explained Seth Page, COO and Head of Strategic Partnerships of ThroughPut Inc. “By partnering with Inteligistics, we can provide customers with our unprecedented supply chain visibility, actionability, predictions and recommendations into customers’ cold chain operations as part of their larger end-to-end supply chain networks. This allows customers to leverage data at every step of the way to make the right produce available at the right place, at the right time, to the right customer, at the best price, in the correct quantities, and in the safest traceable manner possible.”
“Our partnership with ThroughPut.AI will empower agricultural producers, and buyers to leverage data for timely, intelligent decision-making, while accelerating margins,” said Rao Mandava, CEO and Chairman at Inteligistics. “Our customers will now have a unified common operating picture for a single source of truth for all their perishable inventory, enabling them to reduce risk, increase safety, and unlock new growth opportunities. The data is also available for our recently unveiled 1-Click FSMA 204 Traceability reporting solutions. All our supply and cold chain solutions work with data from a company’s legacy data platforms, including ERP, WMS and procurement systems, eliminating the major operational disruption associated with platform replacement.”
Joint Capabilities
Bringing together ThroughPut’s patented and award-winning AI-powered Supply Chain Advanced Analytics and Decision Intelligence solution with Inteligistics’ innovative supply and cold chain performance improvement capabilities will empower their customers to drive additional value in many key areas including the following:
Fill Rate: The joint solution will provide customers with an innovative fill rate model that will enable them to:Dynamically allocate products when farm and producer outputs vary, thus ensuring timely demand fulfillment.Proactively forecast customer demand, pricing, and volumes, as well as leveraging advanced analytics to balance supply with demand on a real-time basis.Tailor fill-rates based on customer segmentation, helping customers to prioritize higher contribution margin product mixes with the best on-time and in-full (OTIF) rates to maximize returns.Scheduling: The combined solution will empower suppliers and buyers to optimize loading facility and cross-docking queuing, slotting, scheduling, loading and usage via:Data-driven recommendations for ideal order fulfillment time-slots based on customer segmentation, available inventory, and priority-based delivery of in-demand products across the supply chain.Ensure necessary labor, docks and slots are available for loading on time to further enhance operational efficiency, greater throughput, higher output, and additional revenue and profit generation.Streamline the scheduling process and maximize order fulfillment while minimizing delays, idle time, and site traffic.Rejection and Discount Rates: Leveraging data inputs from Inteligistics and ThroughPut.AI will deliver fresh Food & Agriculture specific capabilities, including:Actionable insights and recommendations to optimize end-to-end supply chain operations while maintaining traceable product quality and food safety, for a greater bottom-line with enhanced regulatory compliance.Minimize rejection factors by analyzing data on product temperatures, sales history, and movements across supply chain networks to predict the likelihood of rejection or discounts, while reducing rejection rates and discounts in shipments that are fully traceable and quantifiable.Minimize waste and discounts to consumers by managing the inventory from DCs to stores using predictive shelf life and First Expire/First Out distribution.PR Contact
Tina Jacobs
[email protected]
About ThroughPut:
ThroughPut.AI is a Silicon Valley-based Supply Chain AI leader that puts Industrial material flows on Autopilot by leveraging existing Enterprise Data to achieve superior Business, Operations, Financial and Sustainability Results. ThroughPut.AI’s patented, Gartner-recognized AI-powered Supply Chain Analytics and Decision Intelligence software platform predicts Demand, reorients Production Capacity, reassigns Warehouse Space, and reorders Materials optimally, so businesses minimize overpromising and under-delivering, and maximize for their desired outcomes. As a rapid diagnostic platform, ThroughPut.AI both improves material flow and free-cash-flow across the entire end-to-end value chain far faster than leading contemporary and legacy solutions could ever imagine. The founding team is led by seasoned serial entrepreneurs with real-world AI, Supply Chain, Manufacturing, Transportation and Operations experience, from the shopfloor to the top-floor, at leading Fortune 500 Industrial Companies & pioneering Enterprise Technology companies that have impacted the world.
To learn more about ThroughPut Inc, visit our website today.
Additional Resources:
Learn more about ThroughPut Food and Beverage Solution OfferingsFor more information about ThroughPut, visit ThroughPut Resource LibraryRead the ThroughPut Blog and access latest ThroughPut Press CoverageAbout Inteligistics: 
Inteligistics is uniquely placed in perishables industries using Silicon Valley technology and process improvements to bring digital transformation, turn Big Data into clear actions through AI/ML, and deliver high value improvements to supply chain and cold chain performance for perishable commodities. The resulting increase in productivity and reduction in critical cut-to-cool times, resources help meet sustainability goals. Using IoT, off-the-shelf wireless hardware, and proprietary cloud-based applications, Inteligistics develops custom solutions and provides an end-to-end integrated supply chain platform and standalone applications that improve quality, throughput, increase profits and deliver high ROI on the critical process of moving product from field to consumer. Visit inteligistics.com and linkedin.com/company/inteligistics.

View original content:https://www.prnewswire.co.uk/news-releases/throughputai-and-inteligistics-announce-strategic-partnership-to-transform-agriculture-and-fresh-produce-supply-chains-302151475.html

Continue Reading

Trending